← Analyst Upside
AU · rank #15 · 2026-09-07
IMCD
AMSTERDAM · EUR · $6.65B (USD)
SignalBuy2.2strength 2.2 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.844 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 8 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +20.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +8.91% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $103.20 |
| Market cap (USD) | $6.65B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a leading global distributor and formulator of specialty chemicals and ingredients, serving diversified end markets through scale and technical relationships.
Rationale
High analyst upside of 20.9% and strong positive revision momentum are validated by IMCD's H1 2026 results, which featured a Q1 EBITA consensus beat and a sharp Q2 organic recovery.
Material risks
- 1Disintermediation risk if key suppliers or customers bypass IMCD's network to internalize their formulation and distribution capabilities.
- 2Ongoing gross margin compression and integration friction from structurally lower-margin acquisitions like Dong Yang FT and Willows Ingredients, which reduced H1 2026 gross margins by 0.7 percentage points.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed